Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 10/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.59 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | PGR | P06401 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.59 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | SHBG | P04278 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | TNF | P01375 | 1/20 | 0.54 |
| ▸ | IL6 | P05231 | 1/20 | 0.54 |
| ▸ | GLUL | P15104 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142715 | 1.00 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL3488313 | 1.00 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL7137204 | 1.00 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL2087489 | 1.00 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL5084683 | 0.99 | HIF1A (0.62) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL141360 | 0.98 | HIF1A (0.61) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL1535104 | 0.96 | HIF1A (0.63) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL29180381 | 0.96 | HIF1A (0.59) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL141828 | 0.94 | HIF1A (0.62) | HIF1ASMN1; SMN2MAPTPOLBGAA | |
| SCHEMBL4450350 | 0.93 | HIF1A (0.61) | HIF1ASMN1; SMN2MAPTPOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120028910-A1 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS | FOVEA PHARMACEUTICALS (FR) | 2012-02-02 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| EP-1017364-A4 | INORGANIC-POLYMER COMPLEXES FOR THE CONTROLLED RELEASE OF COMPOUNDS INCLUDING MEDICINALS | BUFORD BIOMEDICAL INC (US) | 2006-06-28 | — | — | EP | claimed |
| US-6869976-B2 | Inorganic-polymer complexes for the controlled release of compounds including medicinals | ROYER BIOMEDICAL, INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-6391336-B1 | SOLID COMPOSITION COMPRISING COMPLEXED ACTIVE AGENT DISPERSED THROUGHOUT SOLID CALCIUM SULFATE DIHYDRATE MATRIX | ROYER BIOMEDICAL, INC. | 2002-05-21 | — | — | US | claimed |
| EP-1017364-A1 | INORGANIC-POLYMER COMPLEXES FOR THE CONTROLLED RELEASE OF COMPOUNDS INCLUDING MEDICINALS | Buford Biomedical Inc. (US) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015150-A1 | INORGANIC-POLYMER COMPLEXES FOR THE CONTROLLED RELEASE OF COMPOUNDS INCLUDING MEDICINALS | BUFORD BIOMEDICAL, INC. (US) | 1999-04-01 | — | — | WO | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4646217-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | Stellular Bio, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| WO-1999015150-A1 | INORGANIC-POLYMER COMPLEXES FOR THE CONTROLLED RELEASE OF COMPOUNDS INCLUDING MEDICINALS | BUFORD BIOMEDICAL, INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| CN-1017402-B | Process for preparing steroid ester-containing liposome | BRACO AB (SE) | 1992-07-15 | — | — | CN | disclosed |
| CN-85105713-A | The preparation method who contains the liposome of steroide steroid ester | — | 1987-01-28 | — | — | CN | disclosed |
| EP-0195809-A1 | A LIPOSOMAL SUSTAINED-RELEASE AEROSOL DELIVERY SYSTEM | RIKER LABORATORIES, INC. (US) | 1986-10-01 | — | — | EP | disclosed |
| WO-1986001714-A1 | A LIPOSOMAL SUSTAINED-RELEASE AEROSOL DELIVERY SYSTEM | RIKER LABORATORIES, INC. (US) | 1986-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | HIF1A 1602/4885SMN1; SMN2 1541/4885MAPT 1899/4885 |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | HIF1A 4622/4885SMN1; SMN2 181/4885MAPT 1098/4885 |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | HIF1A 4622/4885SMN1; SMN2 181/4885MAPT 1098/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | HIF1A 1864/4885SMN1; SMN2 1472/4885MAPT 1935/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | HIF1A 1602/4885SMN1; SMN2 1541/4885MAPT 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.